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PHYSIOLOGICAL BASIS OF OVULATION
The Ovarian cortex at puberty contains hundreds of thousands of primordial follicles (1). 
Initially independent of gonadotropins, a cohort (hundreds) of primordial follicles is recruited 
to grow (2). During the early follicle development, the oocyte enlarge and the granulosa cells 
proliferate to form a preantral follicle.  Over 3 – 6 months, the follicle develops FSH receptors 
in the granulosa cells and LH receptors in the theca cells (1). At this stage, antral follicles 
become acutely dependent on FSH for further development (1).  Just before menses,  falling 
estrogen  levels  result  in  with  drawal  of  negative  feed  back  centrally  leading  to  increased 
gonadotropin levels (3). FSH stimulates granulosacell proliferation and differentiation, with the 
development  of  more  FSH  receptors  and  the  production  of  aromatase  (4).  LH  stimulates 
androstenedione  production  by  theca  cells  that  diffuses  in  to  the  granulosa  cell  providing 
substrate for estrogen secretion.  This step is catalysed by the aromatase enzyme, which is 
induced by FSH.  The so called two – cell, two – gonadotropin theory (5,6) postulated that FSH 
concentrations must exceed a certain level (FSH) threshold) before follicular development will 
proceed.
The duration of this period in which the threshold is exceeded (the FSH window) is 
limited in the normal cycle by a gradual decrease in FSH, occurring in the early mid follicular 
phase as a response to negative feed back from rising estrogen levels produced by the larger 
follicles (7). Smaller follicles, with fewer FSH receptors, are no longer stimulated to grow by 
FSH levels below the FSH threshold and undergo atresia (8). Therefore, generally only one 
follicle reaches the stage of ovulation each cycle, despite the fact that hundreds of primordial 
follicles, the number of which varies depending on a woman’s age. FSH induces LH receptors 
in larger antral  follicles above 1 cm in diameter (9).  Rapidly increasing levels of estradiol 
produced by the mature preovulatory follicle precede the mid cycle LH and FSH surge that will 
initiate ovulation.  The circulating level of estradiol determines the time of LH surge.  The 
alteration in  steroidogenic  pathway results  in  progesterone as  the  primary  steroid  hormone 
produced after leutinization (10). The corpus luteum retains the ability to produce estrogen. 
The demonstration of multiple follicular growth (11) suggests that some estrogen in the luteal 
phase is contributed by growing follicles that will under go atresia (12).
The corpus luteum undergoes regression with a fall in progesterone and estrogen and the 
onset of menses.  FSH levels rise with withdrawal of estrogen negative feed back and the next 
cohort of follicles begins to develop.
In summary, normal follicular development culminates in ovulation of a nature oocyte, 
followed by the development of a corpus luteum producing adequate amount of progesterone. 
This sequence of events is orchestrated by the interaction of local ovarian factors and endocrine 
factors from the pituitary and hypothalamus.  The presence of subtle abnormalities despite the 
occurrence of ovulation may be responsible for unexplained infertility.
FUNDAMENTAL TENET OF FOLLICULAR DEVELOPMENT
TWO CELL TWO GONADOTROPIN THEORY (13,14,15)
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ANOVULATION
Anovulation occurs occasionally in all women.  It is probably not uncommon during the 
first 2 or 3 yrs of menstrual life and after the age of 40 yrs, the incidence may rise to as high as 
1 in 5 cycles.  In the active reproductive period, however not more than 1 in 50 regular cycles 
are anovular.   For practical  purpose,  in mature women regular menstruation means regular 
ovulation.
DIAGNOSIS OF OVULATION
Analysis of symptoms
I. Cyclical Bleeding: Regular normal menstrual loss is strong presumptive evidence of 
monthly ovulation.
II. Ovulation pain (Mittleschmerz): Some  discomfort  in  the  hypogastrium or  in  one  or 
other iliac fossa for 12 – 24 hrs just before or just after ovulation.
III. Ovulation Bleeding or discharge (Mittelblut) : Slight loss of blood or of mucus tinged 
with blood at the time of ovulation, sometimes associated with ovulation  pain.
IV. Premenstrual Mastalgia: Premenstrual pain and tenderness in the breasts is related to 
corpusluteum action.
V. Temperature Changes : The biphasic chart is evidence of ovular menstruation.  Rise of 
0.2 – 0.5. C in the luteal phase is due to thermogenic action of progesterone.
VI. Changes  in  Endometrium:   The  evidence  that  ovulation  has  occurred  predicted  by 
secretory activity in the gland during the week preceding or at the onset of menstruation 
by endometrial biopsy.  But is not accurate.
VII. Change in cervical Mucus: At the time of ovulation mucus is thin and profuse with great 
elasticity and with stand stretching up to 10cm – spinn barkeit or thread test.
Vaginal Smear 
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IX. Hormonal Assays: Ovulation  is  confirmed  by  an  estimation  of  mid  luteal  plasma 
progesterone level.  A minimum of 6.5ng/ml indicate ovulation.  Ovulation occur 10 – 
12 hrs after LH peak or 34-36 hours after the initial rise in mid cycle LH.
Hormonal levels in different phases of Menstrual cycle 
Hormone        F.P    Ovulation           L.P        Menstrual
  FSH 5 – 15 m IU/ml       12 – 30 2 – 9    3 – 15
   LH 6 – 14 m IU/ml      25 – 100 2 – 13    3 – 12 
   E2 100 – 200 pg/ml     300 – 500 100 – 200
    P         1 ng/ml                       -   15 ng/ml
Ultrasound
Helpful in the induction and confirmation of ovulation. The graffian follicle grows at the 
rate of 1 -2 mm/day.  Attains the size of 20 mm or more at ovulation
Evidence of
• Sudden shrinkage in size of a follicle
• Appearance of free fluid in POD
• Regrowth of the collapsed cyst
XI Direct observation: The  finding  of  an  active  corpus  luteum on inspecting  the  ovary 
(evidence of stigma)   during laparoscopy or laporatomy.
OVARIAN DYSFUNCTION
According to WHO (1976) classification
Group I                   Hypothalamic pituitary failure
- Anorexia nervosa
- Kallmann’s syndrome
- Sheehan’s syndrome
Group II Hypothalamic pituitary dysfunction
- PCOS
- CAH
- Adrenal tumours
- Androgen producing ovarian tumours
Group III Ovarian failure - Turner syndrome
- Pure gonadal dysgenesis 
- Swyer syndrome
- Autoimmune disorders
- RT/CT
- Infections 
Group IV Congenital  or  Acquired genital  tract  disorders  (Eg)  Imperforate  hymen, 
MRKH syndrome, Asherman’s syndrome.
 Group V Hyperprolactinemia with SOL (Eg) pituitary adenoma. 
Group VI   Hyperprolactinemia  without  SOL  (Eg)  Hypothyroidism,  CRF,  drug 
induced.
Group VII   Amenorrhea  with  an  SOL  with  normal  or  low  PrL  (Eg) 
craniopharyngioma.
POLYCYSTIC OVARIAN SYNDROME (PCOS)
It is a complex disorder with heterogeneous clinical and endocrine factors.  Incidence in 
the reproductive age group is around 20 – 22% (Polson et al 1988) (16).  Polycystic ovaries 
have its origin during adolescence and is thought to be associated with increased weight gain 
during puberty (Belen and Danger 1995) (17).
Clinical features :
 PCOS                                        PCOD (poly cystic appearing ovaries)
Asymptomatic 20%
Obesity 40%
High BMI
Upper body obesity
Infertility 20 – 50%
Ovulatory dysfunction
Abnormal folliculogenesls
                               Hyperandrogenism 66%
                              Acne, hirutism, Alopecia, Seborrhea.
  
Menstrual Irregularity 70%
Oligomenorrhea Amenorrhea 
Intermenstrual 
Menorrhagia  
CRITERIA (1) The NICHD (1990)
(2) The ESHRE & ASRM / Rotterdam (2003)
(3) AES criteria  (2006)
Rotterdam Criteria (1) Oligo / chronic anovulation
DUB
(2) Clinical / Biochemical Evidence of    
Hyperandrogenism
(3) USG E/o polycystic ovaries exclude other causes of 
           hyperandrogenism
Biochemical / Endocrine Abnormalities
1. Raised LH
2. Raised LH: FSH ratio
3. Raised Androgen – Testosterone and androstenedione
4. Raised circulating estrogen
5. Raised fasting Insulin
6. Raised fasting glucose
7. Raised prolactin
8. Decrease in SHBG
9. Raised testosterone : SHBG ratio
Syndrome X (Dysmetabolic Syndrome) (18) :
1. Dysliplidemia - TGL > 140 mg/dl
HDL < 40 mg/dl
2. Insulin resistance, fasting plasma Insulin > 110 mg/dl
3. Obesity BMI > 25 kg /m2   or
   WHR > 0.85 or waist > 100 cm
4. BP > 140 / 90 mm Mg
5.   serum uric aid or   PAI – 1 levels
OVULATION INDUCTION
Ovulation Induction refers to the therapeutic restoration of the release of one egg per 
cycle in the woman who either has not been ovulating regularly or has not been ovulating at all. 
Although it is usually acceptable for OI to result in the release of two eggs, one should avoid 
the ovulation of more than two eggs in an effort to minimize the risk of OHSS and multiple 
gestation.
Appropriate  patient  selection  can  be  a  significant  determinant  of  the  success  of  OI 
among PCOS patients.
Once ovulation has  been documented for  a  particular  treatment.   Patients  should be 
mentally  prepared  to  continue  with  that  regimen for  at  least  3  cycles.   Because  for  most 
treatment the rate of a pregnancy occurring per therapeutic cycle is the same for each of the 
first three cycles.
It  is  mandatory  to  exclude  male  factor  infertility  by  means  of  semen  analysis  and 
bilateral tubal patency by HSG.
OVULATION INDUCTION DRUGS
Induction Agents
1. SERMS - Clomiphene citrate 
2. Aromatase Inhibitors - Letrozole.
Adjuncts
(1) Insulin sensitizers
Menotropins
(2) Gonadotrophins  
        recombinant Gonadotropins 
          pulsatile Gn RH
(3) Gn RH 
     with HMG alone
Gn RH agonist 
     with FSH / HMG
(4) Dopamine Agonists
(5) Dexamethasone
(6) Pretreatment OCPs.
PHARMACOLOGY OF DRUGS
CLOMIPHENE CITRATE
For more than 40 yrs, CC has been the most commonly used oral agent for OI.  In 1961, 
Greenblatt et al., (19), published the first results of OI achieved by CC (at that time known as 
MRL / 41).  But CC is considered pregnancy risk category X.  CC belong to the category of 
SERMs.
SERMs :
1. Designer estrogens with combined effects of estrogen antagonism and partial agonism. 
2. Nonsteroidal analogues with tissue specific activity 
3. Differential modulation of estrogen receptors results in multiple target system.
CLASSIFICATION
1. I  generation Triphenyethylene compounds :
- Tamoxifen
- Toremifene
- Droloxifene
- Idoxifene
- Clomifene
2. II  generation Benzothiophene compounds
- Raloxifene
3. Dihydronaphthylenes
- Trioxifene 
4. Tetrahydronapthylenes 
- Lasofoxifene
5. Benzopyrans -  Ormeloxifene
-  Levormeloxifene
NEWER SERMs
- Ospemifene
- Arzoxifene
- SP 500263
- CHF 4056
- CHF 4227
- FCI 271a
- LY 1271a
- LY 353381
- GTx 006
Other uses of SERMs
- HRT
- Breast ca – adjuvant
- Prevention of osteoporosis
- Cardio protective agent 
CC is an orally administered nonsteroidal ovulatory stimulant designated chemically as 
Molecular formula : 2 –(4 –(2 – Chloro -1, 2- diphenyl ethinyl phenoxy) – N – N – diethyl 
Ethan amine
C28 H28   C1NO . C8 H8 O7  
Molecular weight   - 598.10
Structure
C2H5N CH2 CH2O                                          C6H8O7
Isomers  : CC is a diastereomeric mixture of two geometric isomers 
30% Zuclomiphene (cis isomers, formerly called Transclomiphene)   (Emst et al., 1976).
62% enclomiphene (Trans isomer – formerly called is clomiphene) (Holtkamp et al., 
1987).
Zuclomiphene is mildly estrogenic as well as antiestrogenic.
Enclomiphene is entirely antiestrogenic.
Zuclomiphene is approximately 5 times as potent as enclomphine in inducing ovulation. (20, 
21).
               ZUCLOMIPHENE       ENCLOMIPHENE
Mechanism of Action
- CC acts as competitive antagonist of 17B Estradiol at the level of cytoplasmic nuclear 
receptor complex.
- Blockade of estrogen receptors in the hypothalamic arcuate nucleus leads to an increase 
in Gn RH.
- Increases the pituitary sensitivity to Gn RH (23).
- Increases  pulse  amplitude  but  not  frequency  in  anovulatory  women  with  PCOS,  in 
whom the Gn RH pulse frequency is already abnormally high (24).
- FSH and LH secretion is increased (Dickey et al., 1965) (25).
- Also have a direct effect  on the ovary making the granulosa cells  more sensitive to 
pituitary.
- Hence serum progesterone and estradiol  concentration rises during luteal  phase in a 
direct  dose  response  relation  ship  (Hammond  et  al.,  1982  ;  Fukuma  et  al.,  1983). 
Supraphysiological  levels  of  estrogen can occur  without  central  suppression of  FSH 
because  the  normal  ER-mediated  feed  back  mechanisms  are  blocked  as  a  result  of 
prolonged ER depletion (22). As a result the FSH window being extended – leading to 
multiple follicle growth and a higher multiple pregnancy rate with CC.
Anti estrogenic effects of CC
The endometrium is one of the most important target of antiestrogenic effect of CC (26). 
A  reduction  in  endometrial  thickness  below  the  level  thought  to  be  needed  to  sustain 
implantation was found in up to 30% of women receiving CC (27).  Endometrial thickness < 5 
-6  mm  is  associated  with  failure  to  conceive  (27,28,29).  Deleterious  effect  on  EM  is 
demonstrated by reduction in glandular density and increase in vacuolated cells (30).
PHARMACOKINETICS
CC is excreted principally through intestine 5 days after oral administration 51% has 
been excreted.  However some CC continues to be excreted for at least 6 wks (Mikkelson et al., 
1986).
- Peak plasma concentrations of zuclomiphene occurs 6 hrs after oral administration of 50 
mg. 
- A steady state 25% reached at 48 hrs remains constant for the next 14 days.
- Single  dose  studies  showed  that  Zuclomiphene  (cis)  has  a  longer  half  life  than 
enclomiphene (trans).  Detectable level persisted for longer than a month.
INDICATION  AND  DOSAGE
1. Anovulatory Infertility; PCOS
2. Unexplained Infertility
3. Amenorrhea – Galactorrhea syndrome
4. Psychogenic amenorrhea
5. Post oral contraceptive amenorrhea
6. Certain cases of secondary amenorrhea of undetermined etiology.
DOSAGE
Starting dose 50 mg / day.  A baseline TVS performed on D1 to D3 to exclude ovarian 
cyst. Therapy is begun with in the first 5 days after the onset of a spontaneous or progesterone 
induced menses and continued for 5 days (D3 – D7 of cycle) (31).  US FDA recommends 
maximum dosage of 100 mg /day.  Considerable clinical experience with CC indicates that a 
dosage up to 250 mg/d is safe (32).
If ovulation does not occur after 3 cycles of therapy, further treatment with CC is not 
recommended and the patient should be re evaluated.
ADVERSE EFFECTS %
Ovarian enlargement 13.6% 
Vasomotor flushes 10.4%
Abdominal pain / discomfort 5.5%
Distension / Bloating
Nausea / vomiting 2.2%
Breast discomfort 2.1%
Visual symptoms 1.5%
(Blurred vision, lights, floaters, waves, photophobia, diplopic, scotomata)
Headache 1.3%
AUB 1.3%
The  most  serious  Complication  of  CC  therapy-OHSS(ovarian  Hyperstimulation 
syndrome)
CONTRAINDICATIONS
1. Hypersensitivity
2. Pregnancy
3. AUB of undetermined origin
4. Ovarian cyst
5. Uncontrolled adrenal or thyroid dysfunction or presence of intracranial lesion such as 
pituitary tumors.
CLOMIPHENE SET BACKS
• Discrepancy between ovulatory and pregnancy rates 
• Poor endometrium 30% (peripheral anti estrogenic effect)
• Thickness < 6 mm
• Decreased glandular density
• Decreased uterine blood flow
• Extended FSH window – Multifollicular ovulation 
• Clomiphene resistance (20 – 25% fail to ovulate)
AROMATASE INHIBITORS
A large number of AIs have been developed over the last 30 yrs with the most recent, III 
generation  AIs.
Aromatase  is  a  microsomal  cytochrome  P450  hemoprotein  containing  enzyme  (the 
product of CYP 19 gene) and catalyses the rate limiting step in the production of estrogen. 
Aromatase activity is also present in ovaries, brain, and adipose tissue, muscle, liver, breast 
tissue (33,34).
AROMATASE CONVERTS TESTOSTERONE TO ESTRADIOL
AROMATASE CONVERTS ANDROSTENEDIONE TO ESTRONE
CLASSIFICATION 
Generation Non steroidal Steroidal
I Aminoglutethimide
II Rogletimide, Fadrozole Formestane
III Anastrazole, Letrozole, Exemestane
Vorozole       (suicide inhibitor)
Non selective - Aminoglutethimide, Testolactone (Teslac) 
Selective - Anastrazole Zn 1033 (Arimidex)
Letrozole Gn 20267 (Femara)
Exemestane (Aromasin)
Vorozole (Rivizor)
Formestane (Lentaron)
Fadrozole (Afema)
LETROZOLE
It is a third generation AI.  Highly selective and highly potent inhibitor of Aromatase in 
vitro, in vivo in animals and in humans.
Molecular formula : C17 H11 N5  
Molecular weight : 285.30
MOLECULAR STRUCTURE (35) :
4-4'-(1H-1, 2, 4 - Triazol - 1 - yl  methylene) diabenzonitrite ; 
4-(C4 - cyanophenyl) - (1,2,4 - Triazol - 1 - yl methyl)
MECHANISM OF ACTION
- Block estrogen negative feed back, without depletion of ER.
- Both circulating estrogen and locally produced estrogen in the brain exert negative feed 
back on gonadotropin release  (38 – 41).
- Inhibition of aromatization         Block E production from all sources 
Release  HP  axis  from  estrogenic  negative  feed  back      increase  in  
Gonadotropin    secretion          growth  of  follicles  (Casper   and  Mitwally)  
(42).
- Central feed back mechanisms remains intact. Suppression of FSH & atresia of smaller 
growing follicles occurs causing monoovulation.  
IN PCOS
AI  do  not  antagonize  the  ERs  in  the  brain  and  the  initiation  of  follicle  growth 
accompanied by increasing concentrations of both estradiol  and inhibin results  in a  normal 
negative feed back loop that limits FSH response, thereby avoiding the risk of high multiple 
ovulation and OHSS.
PERIPHERAL MECHANISM OF ACTION
- Increased follicular sensitivity to FSH.
- Temporary accumulation of intraovarian androgen – amplifies FSH effects – stimulates 
IGF–1      synergize with FSH to promote folliculogenesis (43-46).
CHANGES IN THE ENDOMETRIUM
- Upregulation of ERs in the endometrium leading to rapid endometrial growth.
- Increased  endometrial  sensitivity  to  estrogen  resulting  in  more  rapid  proliferation  of 
endometrial  epithelium and stroma and improved flood flow to the uterus (49).   So 
occurs normal endometrial development and thickness.
INDICATIONS 
- Used alone for OI in WHO group II dysfunction.
- As an adjuvant in conjunction with exogenous FSH or other medications to improve the 
out come of OI.
- Induction of ovulation in CC failures (47).
- Along with FSH for  super  ovulation for  IUI or  IVF (50% reduction in  dose  of  FSH 
required) (48).
DOSAGE
- Optimal dosage 2.5 – 5 mg from D3 – D7 
- Single dose 10 – 30 mg on D3 shows similar rates of ovarian stimulation.
- Single high dose 60 mg has been reported without any negative effects.
PHARMACOKINETICS
- Letrozole is rapidly and completely absorbed (99.9% bioavailability). 
- Extensively distributed to tissues.
- Large volume of distribution at steady state (1.87 lt/kg) range (1.47 – 3.24) and 60% 
bound to plasma proteins, mainly to albumin 55%.
- T½  of Letrozole – 42 hrs.
- Area under cure (AUC) is greater in patients with breast cancer due to reduced metabolic 
clearance.   Metabolized  to  a  pharmacologically  inactive  carbinol  metabolite  (4,4’  – 
methanol bis benzo – nitrite) and excreted by kidneys. Of the radiolabel recovered in 
urine, 75% was the glucoronide of carbinol metabolite, 9% - 2 unidentified metabolites 
& 6% - unchanged letrozole.
In  human  liver  microsomes  letrozole  strongly  inhibited  CYP2  A6  and  moderately 
inhibited CYP2c 19.
POTENCY
            I gen                            II gen                                 IIIgen
Aminoglutethimide  4 – OHA 
  92%
 Fadrozole
          93%
                     
 Anastrazole
           92%
 Vorozole
           98%
 Letrozole 99%
 
DRUG INTERACTIONS
Co-administration of Letrozole and Tamoxifen 20 mg resulted in reduction of plasma 
levels of letrozole by 38% (36).
ADVERSE EFFECTS 
 Hot  flushes,  nausea,  vomiting,  weight  gain,  tiredness,  dizziness,  Joint  pain,  unusual 
sweating at night.
 Moderate decrease in lymphocyte counts
 Transient depression
 Thrombocytopenia
 Allergic reaction – rare.
Less common - Constipation
Vaginal dryness
Swelling
Troubled sleep
CONTRAINDICATIONS
In pregnancy
Embryologic and fetotoxic as indicated by
Intrauterine mortality
Increased resorption
Increased post implantation loss
Decreased number of live fetuses 
Total anomalies including absence and
Shortening of renal papilla,
Dilation  of  ureter,  edema  and  incomplete  ossification  of  frontal  
skull and metatarsals 
ADVANTAGES
 Mono follicular ovulation & decreased multiple pregnancy, OHSS & less monitoring
 Good Endometrium
 Convenience of administration & low cost
 Reduction in amount of FSH used for superovulation
 Good safety margin because of short half – life.
REVIEW OF LITERATURE
V ATAY, C CAM, M MUHCU et al 2006 compared Letrozole with CC as a first line 
treatment for OI in with PCOS.  Randomized a total of 106 women with primary infertility. 
Concluded  that  Letrozole  is  associated  with  better  ovulation  induction  16.5%  and  higher 
pregnancy rate and as a first line treatment for anovulatory patients with PCOS. 
A BILJAN AND COLLEAGUES (74) conducted prospective, randomized, controlled 
trial  of  CC  Vs  Letrozole  for  OI  in  women  with  unexplained  infertility  & concluded  that 
Letrozole was an effective alternative to CC in view of monoovulation, endometrial thickness 
and blood flow.  The pregnancy rate was 5.6% in the CC group and 10.7% in the Letrozole 
group.
BASIR et al (10) conducted a comparison study of Letrozole with CC in women with 
unexplained infertility and concluded that Letrozole is effective as a first line treatment for OI.
VENDOLA  et al 1998 studied the use of Letrozole in OI with anovulatory infertility 
and concluded that high risk of ovarian hyperstimulation syndrome and multiple ovulation was 
less compared with CC.
GOSWARNI et al., 2004; SCHOOL CRAFT et al, 2004 ; VERPOEST et al., 2006 
conducted clinical studies of AIs for ovarian stimulation in IVF and have shown that AIs could 
be a low – cost alternative to natural cycle IVF in patients who are poor responders to FSH
MITWALLY AND CASPER, 2001 conducted clinical studies of the use of Letrozole 
for OI.  Ovulation occured in 75% of patients and pregnancy was achieved in 25%
ELNASHAR et al., 2006 conducted studies of use of AIs for OI and concluded that 
Letrozole had an ovulation rate 54.6% and pregnancy rate 25% higher than CC.
ATAY et al, 2006 assessed the efficacy of AIs for OI compared with CC. 106 women 
with oligomenorrhea and PCOS were enrolled.  Results were more favourable in the Letrozole 
group  than  in  CC group regarding  the  percentage  of  ovulatory  cycles  (82.4% Vs  63.6%), 
pregnancy (21.6% Vs9.1%), monofollicular cycles (1.2 Vs 2.4 follicles > 18 mm on the day of 
hcG administration) and endometrial thickness (8.4 mm Vs 5.2 mm).
BAYER et al 2006, 36 patients (95 cycles) were given CC and 38 patients (95 cycles) 
given Letrozole concluded that Letrozole is better than CC in terms of ovulation rate (74.5% 
Vs 65.7%) or pregnancy rates (7.4% Vs 9%)
SOHRABVAND et al 2006 conducted studies on PCOS women resistant to CC and 
concluded that endometrial thickness was higher with Letrozole than CC.
BADAWY et  al 2007 studied  438  infertile  women with  PCOS and concluded  that 
ovulation rate (84% Vs 60%) was better in Letrozole group.  Pregnancy rate (27 Vs 16.6%) and 
endometrial thickness (9.2 Vs 8.1 mm)  was better in Letrozole group than CC group.
AIM OF STUDY
To study about the comparative efficacy of Letrozole Vs clomiphene citrate in ovulation 
Induction in patients with polycystic ovarian syndrome.
MATERIALS AND METHODS
STUDY DESIGN
Cohort study
A prospective, randomized, parallel, multicentric comparative trial
PERIOD OF STUDY
2008 – 2009
PLACE OF STUDY
Department of fertility research clinic, IOG, Egmore
SELECTION OF CASES
100 women belonging to eligible criteria of age (21 – 35 yrs) after obtaining informed 
consent from each participant. 
          ARMS ASSIGNED INTERVENTIONS
1.      Experimental Drug: Letrozole 2.5 mg OD
    for 5 days (D3 – D7)
2.     Active Drug: CC 50 mg OD
        Comparator for 5 days (D3 – D7)
INCLUSION CRITERIA
1. Age : 21 – 35 yrs
2. Period of Infertility
3. PCOS with at least 2 of Diagnostic criteria 
 Oligomenorrhea / Amenorrhea
 Clinical evidence of Acne / hirsutism
  USG evidence of PCOS
4. Normal semen analysis
5. Normal pelvic USG
6. Normal bilateral tubal patency
7. No recent treatment for OI (with in 6 months) 
8. Willingness and giving written informed consent 
EXCLUSION CRITERIA
1. Women with uterine /adnexal pathology (Eg) fibroid, ovarian cyst are excluded from the 
study.
2. Women with clinical features of hyperthyroidism, hypothyroidism are excluded.
3. Those with previous history of any surgeries related to genital tract as per history were 
excluded.
4. Those with impaired hepatic / renal function were excluded
5. Women with RBS> 140 mg/d/ were excluded from the study
6. Age > 35 yrs and obese patients were excluded from this study
7. Lack of willingness.
The  participants  in  this  study  were  subjected  to  history,  clinical  and  biochemical 
evaluation.
1. HISTORY
 Age  (21 – 35 yrs) : An association  between age of the woman and reduced fertility has 
been well documented (65). The decline in fecundability begins in early 30s and accelerates 
during late 30s and early 40s.  Oocyte related decline in fertility is due to decreased ovarian 
reserve (66).
 Period of Infertility : Failure to conceive during 12 – 18 mth despite unprotected regular 
coitus justifies full  investigations.  When the women age > 30 yrs and man > 40 yrs – 
investigations should not be delayed.
 Menstrual History : The patients included in the study were evaluated for history of 
oligomenorrhea,  amenorrhea  & menorrhagia.  In  our  study  women with  oligomenorrhea 
were subjected to the study after progesterone withdrawal bleed.   Women with primary 
amenorrhea were excluded from our study.
 History related to previous surgeries related to genital tract, H/o appendicitis, peritonitis and 
H/o genital  tract TB were excluded from this study.
CLINICAL EXAMINATION
The  patients  enrolled  in  our  study  were  subjected  to  clinical  examination  which 
included.
1. All patients height and weight was measured. BMI was then calculated.
      BMI =  wt in kg. / Ht in m2  It is a reliable indicator, Inexpensive and easy to 
perform.
    
       
Measurement units Formula & Calculations
Kg & m (or cm) wt (kg) / (Ht (m) )2
Ht in cm by 100 = Ht in m
pounds & inches wt (Ib) x (Ht (inches))2   x 703
conversation factor - 703
Interpretation
BMI Weight status
< 18.5 Under weight
18.5 – 24.9 Normal
25.0 – 29.9 Over weight
30.0 – 39.9 Obese
40.0 & More Extreme obesity
2. All patients waist (in cm) and WHR measured
Significance : Upper body obesity (male type) with a WHR > 0.9 associated with higher risk 
of long term morbidity (Pasquali et al., 1994).
3. Clinical  evidence  of  acne,  hirsutism,  acanthosis  nigricans,  hyper  thyroidism  and 
hypothyroidism were looked for in all patients enrolled in our study.
Significance :  Hirsutism and acne are the commonest manifestation and are associated with 
menstrual irregularities and obesity. Usually degree of hirsutism is quantified by Ferriman–
Gallway  scoring  system.   Score  begins  from  o  (no  excusive  terminal  hair  growth)  to  4 
(extensive terminal hair growth) & the numbers added up to maximum of 36.
USG evidence of PCOS : All patients had antral follicle count of at least 10 with size 2 – 9 
mm.  The ovarian volume = / > 10 ml. Evidence of fibroid & ovarian cyst / adnexal masses 
ruled out.
5. Semen Analysis      WHO (2002)    Normal Analysis:
Volume > 2ml
Sperm concentration > 20 million / ml
Sperm motility > 50% progressive or 25% rapidly         
progressive
Morphology > 15% normal form 
White blood cells > 1 million / ml
Immuno bead or mixed anti globulin reaction  test < 10% coated.
In our study, all had  normal semen analysis.
III. Biochemical Investigations
1. Complete blood count, random blood sugar, renal function test and liver function test 
done in all patients.  Any abnormality in any one of these investigations, those patients 
were excluded from this study.
2. For  bilateral  tubal  patency  –  hysterosalpingography  was  performed.   Those  with 
abnormal tubal patency were excluded from our study.
RESULTS AND ANALYSIS
The selected randomized patients were allocated as Group L and Group CC, of which 
Group L patients were administered Letrozole 2.5 mg OD from D3-D7 of the menstrual cycle 
and Group CC patients were administered CC 50 mg OD from D3-D7 of the menstrual cycle. 
Both  the  group  of  patients,  was  subjected  to  transvaginal  ultrasonographic  monitoring  of 
number of follicles, Maximum diameter of the largest follicle, and endometrial thickness from 
D11 onwards. The serum progesterone levels were measured on Day 21 which indicates the 
definite occurrence of ovulation. The treatment was discontinued in both the groups, if patients, 
developed ovarian enlargement.
The  number  of  follicles,  mean  diameter  of  the  largest  follicle,  ovulation  rate, 
endometrial thickness and serum progesterone values were compared in the two groups.  A 
group test or the students test was used to compare data as appropriate.  A value < 0.05 was 
considered to be statistically significant.
TABLE - 1
AGE GROUP - CROSS TABULATION
Age 
Group
Group
L CC Total
21-25 
Yrs.
Count 
% within Group
72
72.0%
71
71.0%
143
71.5%
26-30
Yrs.
Count 
%  within Group
20
20.0%
18
18.0%
38
19.0%
31-35 
Yrs.
Count 
%  within Group
8
8.0%
11
11.0%
19
9.5%
Total Count %  within Group
100
100.0%
100
100.0%
200
100.0%
CHI-SQUARE TESTS
Value df
Asymp. Sig.
(2-sided)
Pearson Chi-square 0.586a 2 0.746
Likelihood Ratio 0.588 2 0.745
Linear-by-Linear 
Association
0.187 1 0.665
N of Valid Cases 200
a 0 cells (.0%) have expected count less than 5. The minimum expected  count is 9.50.
GROUP STATISTICS
Age Group N Mean Std. Deviation
Std. Error 
Mean
L 100 24.8800 3.18862 0.31886
CC 100 25.1600 3.32338 0.33234
The table shows the mean, standard deviation, in both groups L & CC with respect to 
age the mean age in Group L is 24.8 years. The mean age in Group CC is 25.1 years. Both 
groups are comparable, by applying the chi-square test,  chi-square value 0.586 and p-value 
0.746 are obtained. P value being > 0.05 is not significant.
TABLE - 2
MEAN DURATION OF  INFERTILITY
Independent Samples Test
Group Statistics
Duration of 
Infertility Group N
Std. 
Deviation p Value
L 100 2.4400 0.60836
CC 100 2.4300 0.59041 0.906
The mean duration of infertility in Group L is 2.44 years and in Group CC is 2.43 years 
with p value is 0.906 (> 0.05). Not significant Both the groups are comparable with respect to 
mean duration of infertility.
TABLE - 3
GROUP STATISTICS
BMI Group N Std. Deviation p Value
L 100 22.5300 3.13831
CC 100 22.6880 3.74226 0.747
The mean body mass Index in Group L is 22.53 with S.D. of 3.138. The mean body 
mass Index in Group CC is 22.68 with S.D. of 3.742.
Both the groups are comparable with respect to body mass Index with p value 0.747 (> 
0.05) not Significant.
TABLE - 4
GROUP STATISTICS
Wait Hip 
Ratio Group N
Std. 
Deviation p Value
L 100 0.8276 0.2675
CC 100 0.8273 0.2831
0.939
The mean WHR in Group L is 0.8276 with S.D. of 0.267 Group CC is 0.827 with S.D. 
of 0.283.
Both the groups are comparable with respect to WHR with p value 0.939 (>0.05) Not 
Significant.
TABLE - 5
HIRSUTISM GROUP
Hirsutism
Group
L CC
Total
No 
Hirsutism
Count 
% within Group
83
83.0%
78
78.0%
161
80.5%
Hirsutism Count %  within Group
17
17.0%
22
22.0%
39
19.5%
Total Count %  within Group
100
100.0%
100
100.0%
200
100.0%
CROSS TAB
Oligo
Menorrhea
Group
L CC
Total
No Oligo 
Menorrhea
Count 
% within Group
74
74.0%
73
73.0%
147
73.5%
Oligo 
Menorrhea
Count 
%  within Group
26
26.0%
27
27.0%
53
26.5%
Total Count %  within Group
100
100.0%
100
100.0%
200
100.0%
AMENORRHEA GROUP
CROSS TAB
Amenorrhea
Group
L CC
Total
No 
Amenorrhea
Count 
% within Group
83
83.0%
77
77.0%
160
80.0%
Amenorrhea Count %  within Group
17
17.0%
23
23.0%
40
20.0%
Total Count %  within Group
100
100.0%
100
100.0%
200
100.0%
17% of the cases in Group L had clinical evidence of hirsutism. 22% of the cases in 
Group CC had hirsutism.
26% of the cases in Group L and 27% of the cases in Group CC had oligomenorrhea.
17%  of  the  cases  in  Group  L  and  23%  of  the  cases  in  Group  CC  has  history  of 
amenorrhea.
After excluding pregnancy by urine gravindex method, these patients were subjected to 
the study after progesterone withdrawal bleed.
TABLE - 6
OVULATION GROUP
Ovulation
Group
L CC
Total
Not Ovulated Count % within Group
33
33.0 %
48
48.0%
81
40.5%
Ovulated Count %  within Group
67
67.0 %
52
52.0 %
119
59.5 %
Total Count %  within Group
100
100.0%
100
100.0%
200
100.0%
CHI-SQUARE TESTS
df
Asymp. 
Sig.
(2 sided)
Exact 
Sig.
(2-sided)
Exact 
Sig.
(1-sided)
Pearson Chi-square 9.778b 1 0.002
Continuity Correction 8.909 1 0.003
Likelihood Ratio 9.862 1 0.002
Fisher’s Exact Test 0.003 0.001
Linear-by-Linear
Association 9.729 1 0.002
N of Valid Cases 200
The ovulation response group tabulation shows that of 100 patients in L group, 67% 
ovulation occurred. 52% ovulation rate occurred in CC group. By applying chi-square tests, 
chi-square  value  8.909  p  value  0.003.  (<0.05)  =  Significant.  This  shows  that  there  is 
statistically  significant  difference in ovulation induction rate  between the group of  patients 
treated patients with L and CC. Letrozole treated patients had better ovulation rates than CC.
NUMBER OF FOLLICLES IN L & CC GROUP
Number of 
follicles
Group
L CC
Total
No
Follicle
Count 
% within Ovulation
33
33.0%
48
48.0%
81
40.5%
One 
Follicle
Count 
% within Ovulation
52
77.6%
6
11.5%
58
29.0%
Two 
Follicles
Count 
% within Ovulation
15
22.4%
23
44.2%
38
19.0%
Three 
Follicles
Count 
% within Ovulation
0
0.0%
23
44.2%
23
11.5%
Total Count % within Ovulation
67
100.0%
52
100.0%
200
100.0%
CHI-SQUARE TESTS
df Asymp. Sig.(2 sided)
Pearson Chi-square 100.000a 3 0.000
Likelihood Ratio 138.469 3 0.000
Linear-by-Linear 
Association 84.366 1 0.000
N of Valid Cases 100
a. 2 cells (25.0%) have expected count less than 5. The minimum expected count is 2.88.
The cross tabulation shows that of 100 patients studied in Letrozole group, 52% of the 
cases developed single follicle, 15% of the cases developed two follicles. 33% of the cases did 
not ovulate with Letrozole.
Of 100 patients in CC group, 6% of the cases developed single follicle, 23% of the cases 
developed two follicle, 23% of the cases developed three follicles. 48% of the cases did not 
ovulate with CC therapy. By applying the chi-square tests, chi-square value 63.945 and p value 
= .000 (< 0.05) highly significant.
Letrozole treated cases had better monofollicular ovulation rates than CC treated group.
TABLE 8
GROUP STATISTICS
Size of 
Follicle Group N
Std. 
Deviation p Value
L 67 21.1560 2.40499
CC 52 18.7635 2.35614
< 0.05
The table shows the mean diameter of largest follicle in L group is 21.15 mm with a 
S.D. of 2.404. In CC group, the mean diameter is 18.76 mm with a S.D. of 2.356 p value of 
0.000 (<0.05) obtained which is highly significant.
TABLE 9
GROUP STATISTICS
Endometrial 
Thickness Group N
Std. 
Deviation p Value
L 67 8.6090 0.43753
CC 52 7.1115 0.60929
0.000
(<0.05)
The table shows the mean endometrial thickness in L group is 8.60 mm with a S.D. of 
0.437.
In CC group the mean Endometrial thickness is 7.11 m with a S.D. of 0.609 P value 
obtained is 0.000 (<0.05) = High Significant.
TABLE – 10
GROUP STATISTICS
Serum 
Progesterone 
Level
Group N Std. Deviation
Std. 
Error 
Mean
L 67 13.4164 1.57688
CC 52 12.2788 1.87191
0.000
(< 0.05)
The table shows the mean serum progesterone level in L group is 13.41 ng/ml  CC group 
is 12.27 ng/ml. p value of 0.000 (< 0.05) = Highly Significant.
DISCUSSION
A prospective randomized study was conducted in IOG during January 2008- Feb 2009. 
Of  200 patients  who attended the  infertility  clinic  100 patients  recruited  in  L group were 
allocated to receive 2.5 mg OD from D3-D7 of the menstrual cycle. 100 patients recruited in CC 
group were allocated to receive 50 mg OD from D3-D7 of the menstrual cycle. Both groups 
were comparable with respect of age, mean duration of infertility, BMI and WHR which had no 
statistically significant difference.
The patients recruited in both the groups were evaluated for evidence of acne, hirsutism, 
oligo / amenorrhea.
Our patients enrolled in both the groups were also evaluated for the presence of clinical 
evidence of hyperthyroidism and hypothyroidism.
In our study 17% of cases in L group and 22% of cases in CC group had hirsutism. 17% 
of   cases  in  L group  and 23% of  cases  in  CC group had  a  history  of  amenorrhea.  After 
excluding pregnancy for these patients by performing an urine gravindex method, these patients 
were  included in our study after progesterone withdrawal bleed.  
Both group were compared with respect of number of follicles, mean diameter of largest 
follicle, mean endometrial thickness and serum progesterone levels. The patients enrolled in 
both groups had no complications pertaining to L and CC during our period of study.
BADAWY et al., 2007 studied 438 infertile women with polycystic ovarian syndrome 
and concluded that  ovulation  rates  was  better  in  L group (84% Vs 60%) and endometrial 
thickness was better in L group than CC group (9.2 vs 8.1 mm).
In our study, the ovulation rate in L group was 67% and that of CC group 52%
VATAY, C CAM M MUHCU et al., in his study concluded that L is associated with 
better  ovulation  rate  and can  be  used  as  first  line  treatment  for  anovulatory  patients  with 
polycystic ovarian syndrome.
In our study, 52% of the cases had monofollicular ovulation in L group where as in CC 
group only 6% of the cases developed single follicle and 23% of the cases developed two 
follicles.
BILJAN AND COLLEAGUES in his study concluded that Letrozole was an effective 
alternative to CC in view of monoovulation.
BASIR et al., in his study concluded that L is an effective alternative to CC for OI.
In our study, the mean endometrial thickness was better in Letrozole group than CC 
group (8.6 mm vs 7.1 mm).
The mean endometrial thickness (7.1 mm) in CC group indicates the adverse effects of 
CC  on  the  endometrial  growth  that  is  thought  to  be  due  to  depletion  of  the  endometrial 
receptors.
SOHRABVAND  et al., in his study concluded that Endometrial thickness was higher 
with L group than CC Group.
In our study the mean diameter of largest follicle was greater in L group than CC group 
(21.15mm Vs  18.76  mm).  The  serum progesterone  levels  measured  on  D21  indicated  the 
definite occurrence of ovulation was 13.41 ng/ml in L group and 12.27 ng/ml in CC group.
MITWALLY  et  al., in  his  study  reported  that  use  of  letrozole  is  associated  with 
significantly  lower  multiple  pregnancy  rates  they  explained  this  results  by  the  fact  that 
Letrozole induce limited number of mature follicles.
In a similar study, sh Tehrani Nejad,  et  al., (Journal  of Assisted Reprod and Genet, 
2008) demonstrated that Letrozole was a better alternative to cc-gonadotropin in patients with 
unexplained infertility (63).
BEGUM MR, FERDOUS J, QUADIR E in his studies concluded that Letrozole has 
better ovulation and pregnancy rates in comparison to CC in patients with PCOS (64).
SUMMARY
In the patients recruited in this study, 
1. The mean age in L group was 24.8 yrs and in CC group 25.1. years.
2. The mean duration of infertility in L group was 2.43 years and in CC group 2.44 
years.
3. In Letrozole group, the ovulation  rate was 67% and in CC group 52%.
4. In Letrozole group, 52% of the cases developed single dominant follicle and 15% 
of the cases had developed two dominant follicles.
5. In CC group only, 6% of the cases had monofollicular ovulation and 23% of the 
cases developed two follicles.
6. The mean diameter of largest follicle in L group is 21.15 mm and in CC group 
18.76 mm.
7. The mean endometrial thickness is L group is 8.6 mm and in CC group 7.1 mm.
8. The serum progesterone level in L group is 13.41 ng/ml and CC group is 12.27 
ng/ml.
CONCLUSION
Letrozole is more effective in inducing ovulation in patients with an ovulatory cycles 
than clomiphene citrate in terms of monofollicular ovulation and a better endometrial thickness 
than when compared with clomiphene citrate. The mean diameter of the largest follicle and the 
serum progesterone level  studied showed letrozole  was  superior  than clomiphene citrate in 
inducing ovulation. Hence Letrozole can be recommended as the first line drug for ovulation 
induction in anovulatory patients with polycystic ovarian syndrome.
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PROFORMA
NAME :
AGE :
OCCUPATION :
SOCIO ECONOMIC STATUS :
MARITAL STATUS :
PERIOD OF INFERTILITY :
HEIGHT :
WEIGHT :
BODY MASS INDEX (kglm2 ) :
WAIST (CM ) :
WAIST  HIP  RATIO :
SEMEN ANALYSIS :
MENSTRUAL HISTORY :
OLIGOMENORRHEA :
AMENORRHEA :
CLINICAL EVIDENCE  OF :
ACNE :
HIRUSTISM :
ACANTHOSIS NIRGICANS :
HYPERTHYROIDISM :
HYPOTHYROIDISM :
USG EVIDENCE OF PCOS :
INVESTIGATIONS 
COMPLETE BLOOD COUNT :
RENAL FUNCTION TEST :
LIVER FUNCTION TEST :
USG – FIBROID, OVARIAN CYST :
HYSTEROSALPINGOGRAM – FOR TUBAL PATENCY
PREVIOUS HISTORY OF SURGERY – YES / NO
RECENT TREATMENT FOR OVULATION INDUCTION 
( WITH IN 6 MONTHS ) – YES / NO
ABBREVIATIONS
FSH - Follicle stimulating hormone
LH - Leutinizing harmone
CAMP - Cyclic Adenosine monophosphate
LDL - Low density Lipoprotein
HCG - Human chorionic Gonadotrophin
FP - Follicular Phase
L.P. - Luteal Phase
POD - Pouch of Douglas
PCOS - Polycystic ovarian syndrome
CAH - Congenital Adrenal Hyperplasia
MRKA - Meyer – Rokitansky Kuster Hauser syndrome
SOL - Space occupying lesion 
PrL - Prolactin
NICHD - National  Institute  for  Child  Health  and  Human 
Development
ESHRE - European Society for Human Reproduction
ASRM - American Society for Reproductive Medicine
AES - Androgen Excess Society
TGL - Triglycerides
HDL - High Density Lipoprotein
BMI - Body mass Index
WHR - Waist Hip Ratio
PAI - Plasminogen Activator Inhibitor 
OI - Ovulation Induction
OHSS - Ovarian Hyperstimulation Syndrome
HSG - Hysterosalpingrography
SERMs - Selective Oestrogen Receptor Modulators
GnRH - Gonadotropin Releasing Harmone
HMG - Human Menopausal Gonadotropin
OCP - Oral contraceptive pill
L - Letrozole
CC - Clomiphene Citrate
HRT - Hormone Replacement Therapy
TVS - Transvaginal Ultrasonography
AUB - Abnormal Uterine Bleeding
AI - Aromatase Inhibitors
ER - Estrogen Receptor
HPA - Hypothalamic Pituitary Axis
IGF-1 - Insulin like Growth factor – 1
RBS - Random Blood Sugar
KEY TO MASTER CHART
Sl.No. - Serial Number
M/s. - Duration of Infertility
Ht - Height
Wt - Weight
BMI - Body Mass Index
WHR - Waist Hip Ratio
Oligo - Oligomenorrhea
Amen - Amenorrhea
EMT - Endometrial Thickness
Prog - Progesterone
Group 1 - Letrozole
Group 2 - Clomiphene citrate
